Table 1.

Demographics and baseline clinical characteristics of the patients and clinical samples

Patients	Number (%) (n = 85)	Median [IQR]
Age (years)		64 [54–69]
Male	62 (73)
Co-morbid conditions
Heart transplant	10 (12)
Lung transplant	10 (12)
COPD	14 (16)
Active chemotherapy for cancer*	6 (7)
AIDS	5 (6)
Chronic dialysis	3 (4)
Clinical samples	Number (%) (n = 95)	Median [IQR]
Pneumonia
Ventilator-associated	71 (75)
Ventilated hospital-acquired	24 (25)
Severity of disease
Days in intensive care		5.6 [3.5–14]
SAPS II score		59 [36–72]
Days of mechanical ventilation		5.5 [3.4–11]
Relapse of pneumonia	24 (25)
Deaths	30 (32)
Laboratory
ESBL carrier	23 (24)
MRSA carrier	1 (1)
Antibiotics in the 7 days before the episode of pneumonia**	41 (43)
Cefotaxime	11 (12)
Piperacillin-tazobactam	7 (7)
Amikacin	7 (7)
Cefepime	6 (6)
Metronidazole	5 (5)
Sampling
Bronchoalveolar lavage	72 (76)
Plugged telescoping catheter	23 (24)
Turnaround time of Unyvero HPN (hours)		4.6 [4.4–5]
Lysis		0.5 [0.5–0.5
Waiting time		0.1 [0.1–0.4]
Analysis		3.8 [3.8–3.8]

*Three patients with lung cancer, 2 with esophagus cancer, and one with melanoma

**Only the 5 most frequently prescribed antibiotics are reported